chloroquine has been researched along with Dysplastic Nevus Syndrome, Hereditary in 1 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Excerpt | Relevance | Reference |
---|---|---|
"Melanoma is one of the most common skin infections, has triggered significant morbidity and mortality across the globe." | 5.72 | In silico-prediction of chloroquine as a multi-targeted drug against CDKN2A signaling network associated with cutaneous malignant melanoma. ( Aqeel, M; Awan, L; Bashir, Z; Jan, Z; Kalsoom, S; Muhammad Ali, G; Munir, A; Nadeem, T; Sadia, H; Saeed, A; Ud Din, S, 2022) |
"Melanoma is one of the most common skin infections, has triggered significant morbidity and mortality across the globe." | 1.72 | In silico-prediction of chloroquine as a multi-targeted drug against CDKN2A signaling network associated with cutaneous malignant melanoma. ( Aqeel, M; Awan, L; Bashir, Z; Jan, Z; Kalsoom, S; Muhammad Ali, G; Munir, A; Nadeem, T; Sadia, H; Saeed, A; Ud Din, S, 2022) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Jan, Z | 1 |
Aqeel, M | 1 |
Munir, A | 1 |
Saeed, A | 1 |
Sadia, H | 1 |
Kalsoom, S | 1 |
Nadeem, T | 1 |
Bashir, Z | 1 |
Awan, L | 1 |
Ud Din, S | 1 |
Muhammad Ali, G | 1 |
1 other study available for chloroquine and Dysplastic Nevus Syndrome, Hereditary
Article | Year |
---|---|
In silico-prediction of chloroquine as a multi-targeted drug against CDKN2A signaling network associated with cutaneous malignant melanoma.
Topics: Chloroquine; Cyclin-Dependent Kinase Inhibitor p16; Humans; Melanoma; Melanoma, Cutaneous Malignant; | 2022 |